Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.040
-0.080 (-3.77%)
Oct 30, 2025, 1:11 PM EDT - Market open

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.

The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease.

It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.

Palisade Bio, Inc.
Palisade Bio logo
CountryUnited States
Founded1996
IndustryBiotechnology
SectorHealthcare
Employees8
CEOJ. Finley

Contact Details

Address:
7750 El Camino Real, Suite 2A
Carlsbad, California 92009
United States
Phone858 704 4900
Websitepalisadebio.com

Stock Details

Ticker SymbolPALI
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001357459
CUSIP Number696389105
ISIN NumberUS6963894026
Employer ID52-2007292
SIC Code2836

Key Executives

NamePosition
J. D. FinleyChief Executive Officer, Chief Financial Officer and Director
Dr. Mitchell Lawrence Jones M.D., Ph.D.Chief Operating Officer and Chief Medical Officer
Dr. Joerg Heyer Ph.D.Head of Translational Science and Medicine
Ryker WillieSenior Vice President of Finance and Corporate Controller

Latest SEC Filings

DateTypeTitle
Oct 28, 2025DEF 14AOther definitive proxy statements
Oct 22, 20258-KCurrent Report
Oct 20, 20258-KCurrent Report
Oct 17, 2025PRE 14AOther preliminary proxy statements
Oct 16, 20258-KCurrent Report
Oct 9, 20258-KCurrent Report
Oct 9, 2025SCHEDULE 13GFiling
Oct 9, 2025SCHEDULE 13GFiling
Oct 8, 2025SCHEDULE 13GFiling
Oct 8, 2025SCHEDULE 13GFiling